Based on the key indicators related to RAPT Therapeutics' liquidity, profitability, solvency, and operating efficiency, RAPT Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, RAPT Therapeutics' Short Term Debt is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 157.8 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 119 M in 2024. Key indicators impacting RAPT Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for RAPT Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor RAPT Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in RAPT Therapeutics.
Net Income
(110.96 Million)
RAPT
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Capital Surpluse
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Net Working Capital
Common Stock
Property Plant Equipment
Current Deferred Revenue
Short Term Debt
Retained Earnings Total Equity
Short Term Investments
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Gross Profit
Cost Of Revenue
Non Operating Income Net Other
Probability Of Bankruptcy
Understanding current and past RAPT Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of RAPT Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in RAPT Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.
RAPT Therapeutics Stock Summary
RAPT Therapeutics competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what RAPT Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining RAPT Therapeutics's current stock value. Our valuation model uses many indicators to compare RAPT Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RAPT Therapeutics competition to find correlations between indicators driving RAPT Therapeutics's intrinsic value. More Info.
RAPT Therapeutics is rated second in return on equity category among its peers. It is rated fifth in return on asset category among its peers . At this time, RAPT Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value RAPT Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
RAPT Therapeutics Systematic Risk
RAPT Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. RAPT Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on RAPT Therapeutics correlated with the market. If Beta is less than 0 RAPT Therapeutics generally moves in the opposite direction as compared to the market. If RAPT Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one RAPT Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of RAPT Therapeutics is generally in the same direction as the market. If Beta > 1 RAPT Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in RAPT Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various RAPT Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of RAPT Therapeutics growth as a starting point in their analysis.
RAPT Therapeutics November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of RAPT Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of RAPT Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of RAPT Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing RAPT Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build RAPT Therapeutics's daily price indicators and compare them against related drivers.
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.